Top AI Companies With Best Stability & Growth (7,016)

Strong Revenue Growth: Revenue and test volumes are rising, with 2025 total revenue up year over year to $147.2M, U.S. Galleri revenue up, and more than 185,000 tests sold; quarterly updates also showed double‑digit growth.

Strategic Partnerships: Access expanded through TRICARE coverage, Quest Diagnostics ordering integration, digital‑health channels, and health‑system/EHR integrations, alongside international collaborations such as Samsung and a Canada launch.

Investor Backing & Capital Strength: Funding raised in 2025 and a reported cash balance exceeding $850M provide runway into 2030, supporting continued commercialization and regulatory efforts.

Resilient & Sustainable Growth: PwC posted consecutive record global revenues through FY2024 and FY2025, evidencing continued growth even as the environment cooled. Gains extended across Assurance, Advisory, and Tax & Legal, with the Americas providing notable momentum.

Innovation-Driven Growth: Large, ongoing investments in AI and platform modernization, including a next‑generation audit capability, are positioned as engines for future expansion. Alliance‑enabled offerings and scaling managed services have been cited as recent growth drivers.

Strong Market Position & Advantage: A broad global footprint serving a significant share of the world’s largest companies underpins revenue stability. Breadth across services and industries supports durability when demand varies by territory.

Strong Revenue Growth: Revenue continues to rise at a double‑digit pace year over year with acceleration into year‑end. Management reaffirmed guidance for another year of meaningful top‑line expansion.

Market Expansion: The customer base and analysis volumes increased to record levels, and two large U.S. integrated health systems are expected to add substantial annual throughput as implementations ramp in the second half of 2026. Net dollar retention improved, indicating deeper adoption within existing institutions.

Strategic Partnerships: Collaborations with leading cancer centers and biopharma (e.g., MSK‑ACCESS powered with SOPHiA DDM, AstraZeneca, MD Anderson) are expanding product adoption and opening key U.S. channels. These alliances signal validation of the platform and support growth in high‑value applications like liquid biopsy.

Strong Revenue Growth: Estimates indicate revenue scaled from roughly $600M run‑rate in 2024 to about $900M annualized by October 2025, implying continued double‑digit growth into 2026. Company communications emphasize rising transaction volumes and network performance consistent with this trajectory.

Investor Backing & Capital Strength: A $335M secondary in January 2025 lifted valuation to approximately $3.5B, signaling investor confidence and providing liquidity ahead of a potential 2026 IPO window. The step‑up from a 2022 valuation suggests continued access to capital to fund expansion.

Product Line Growth: The platform broadened with Rokt Pay+ and acquisitions including Aftersell and mParticle (about $300M in January 2025) to deepen wallet share and cross‑selling across ecommerce and commerce media. These moves expand the product surface area beyond core placements.

Profitability: Recent results show adjusted EBITDA increased in Q4 FY2026 with year-over-year margin expansion, reflecting cost discipline. Management also highlighted improved margins alongside traction for its AI-native Percipio platform.

Healthy Cash Flow: Quarterly free cash flow improved to $27M in Q4 FY2026 from $13M, indicating stronger cash generation. Disclosures attribute this to tighter cost control and operational execution.

Innovation-Driven Growth: The company launched its next‑generation AI-native Percipio platform and tools like CAISY, reporting sharp increases in AI engagement and early enterprise customer wins. Management framed these developments as supporting improved unit economics and potential re-acceleration in the core.

Investor Backing & Capital Strength: Recent late-stage funding rounds and a higher valuation are presented as clear signals of substantial capital support and investor confidence. The company indicates plans to deploy this capital toward team growth and product development across core markets.

Strong Revenue Growth: Management reports crossing a major ARR milestone with multiple years of rapid top-line expansion. Consistent year-over-year acceleration is highlighted alongside continued scaling plans.

Market Expansion: The business is extending beyond housing into healthcare and signaling international ambitions. New office hubs and active hiring across functions support broader geographic and vertical reach.

Product Line Growth: Observations indicate Snyk Code surpassed a major ARR milestone in 2024, with continued launches across SAST, SCA, DAST/API, and AI‑security through 2025–2026. Public updates also highlight ongoing feature velocity (e.g., IDE/CLI upgrades, agent‑focused security) and platform expansion via acquisitions.

Strategic Partnerships: Public recognition such as Google Cloud’s 2025 Technology Partner of the Year and an active 2026 partner ecosystem suggest durable go‑to‑market channels. Company events and a channel‑first motion are described as supporting enterprise adoption and pipeline.

Resilient & Sustainable Growth: Disclosures indicate ARR advanced beyond the $300M milestone reached in late 2024 into early 2026, reflecting continued though moderated expansion. Independent estimates and company commentary together portray steady ARR progression despite a more mature core business.

Profitability: Udemy delivered its first full year of positive net income in 2025 and expanded adjusted EBITDA margins, indicating improved earnings quality. The shift toward subscriptions and disciplined execution supported margin expansion.

Future-Ready Strategy: Management is pivoting the model to recurring subscriptions across enterprise and consumer, lifting the revenue mix toward more predictable streams and improving margins. Rapid engagement in AI learning and the announced Coursera all‑stock merger signal preparation for evolving demand and potential scale benefits.

Strong Market Position & Advantage: Udemy reported 79 million learners and 17,216 enterprise customers by early 2025, with enterprise net dollar retention stabilizing and stronger among large customers. This scale and resilience in larger accounts suggest an entrenched footprint in corporate learning.

Product Line Growth: The company rebranded to Intellistack and launched the AI‑native Streamline platform with a CLM module, maintaining monthly feature releases into early 2026. This broadens scope beyond legacy forms/doc/e‑sign into end‑to‑end workflow orchestration.

Market Expansion: Positioning highlights large enterprise and regulated customers (e.g., healthcare) and Salesforce‑centric workflows, alongside a new Healthcare Advisory Board and invitations for increased SI investment in 2026. These moves indicate an up‑market push and deeper focus in priority verticals.

Investor Backing & Capital Strength: Backing from PSG Equity and Silversmith Capital Partners, including a $425M growth investment announced in 2021, provides resources to fund product and go‑to‑market initiatives. Continued operation of Formstack/Formsite alongside Streamline signals capacity to support expansion.

Investor Backing & Capital Strength: Recent announcements of a $32M Series A (March 2024) and an oversubscribed $50M Series B (April 2025, including $20M credit) indicate strong access to capital. These rounds are positioned to fund product expansion, go‑to‑market, and hiring.

Strategic Partnerships: The TriNet collaboration (October 2023, highlighted again in May 2025) and joining the Workday Wellness Program (April 2026) show expanding distribution through major HR platforms. These channels enhance reach into SMB and broader employer segments.

Market Expansion: Company communications and coverage cite surpassing 15,000 customers and momentum in the mid‑market. Channel distribution via platforms like TriNet is presented as widening access to employer groups.

Strong Revenue Growth: Q4 FY2026 revenue rose 46% year over year to $377.7M and full‑year FY2026 revenue grew 48% to $1.32B. Management guides FY2027 revenue to about $1.60B, signaling continued expansion.

Healthy Cash Flow: Free cash flow improved markedly to $237.8M for FY2026 versus $21.6M in FY2025. Quarterly results also showed positive free cash flow, indicating stronger cash generation alongside growth.

Strong Market Position & Advantage: Independent analyst frameworks (e.g., Gartner MQ 2025; IDC 2025) and industry coverage place the company among leaders in backup/data protection and cyber‑recovery. Large‑enterprise traction is evident with 2,805 customers at $100K+ ARR, up year over year.

Innovation-Driven Growth: FDA clearance of the eVO2peak module in December 2025 and multiple FDA‑cleared algorithms, alongside the physIQ acquisition adding mature analytics and biosensor pipelines, point to expanding technical capabilities. Active clinical programs (e.g., the OCORO all‑remote study) and conference presence indicate continued product and evidence development.

Market Expansion: Operations span 26+ countries with stated plans to extend access to Europe and Asia by 2026, signaling geographic scaling. Regulatory momentum and multi‑million hours of on‑body data suggest readiness to support broader deployment across markets.

Strong Hiring & Retention: A reported 51–200 employee range, 32 new hires in 2025, and ongoing postings (e.g., Director of Regulatory Affairs) reflect organizational scaling. Quality certifications (ISO 13485/MDSAP) and a dedicated production operations suite underscore maturing infrastructure alongside headcount growth.

Investor Backing & Capital Strength: Public signals indicate strong investor confidence, including a 2022 Series D at a unicorn valuation and a 2025 definitive agreement to be acquired by STG. Feedback suggests this capital support underpins continued scaling and product investment.

Innovation-Driven Growth: The company continues to ship AI-driven product enhancements and expand availability (e.g., Da Vinci and Studio) with active customer case studies into 2025–2026. Feedback suggests sustained product velocity is driving adoption and performance gains.

Profitability: Company communications describe the business as profitable with high net retention. Such fundamentals indicate a durable base for reinvestment and stability.

Investor Backing & Capital Strength: Funding in late 2024 added $40M and brought total capital cited to roughly $83M–$106M, according to coverage and company materials. Feedback suggests this expanded runway is supporting hiring and go‑to‑market execution.

Innovation-Driven Growth: Product velocity remains high with the April 2026 launch of Copilot and ongoing releases that broaden AI agent capabilities and real‑time metrics. Feedback suggests this cadence reflects sustained R&D investment and platform expansion.

Strategic Partnerships: A 2025 strategic partnership with TaskUs and ecosystem ties (e.g., 8x8 and voice technology partners) indicate strengthening distribution and enterprise credibility. Feedback suggests these relationships help validate use cases and accelerate adoption.

Strong Revenue Growth: Revenue grew strongly in FY2025 and Q4, and management still guides double‑digit expansion into 2026. Rising remaining performance obligations further indicate contracted growth ahead.

Customer Loyalty & Retention: Net dollar retention was healthy overall and even stronger within larger customer cohorts, indicating ongoing expansion within accounts.

Product Line Growth: New products and AI capabilities showed rapid traction, with offerings like monday vibe surpassing $1M ARR quickly and adjacent products contributing a growing share of ARR.

Strong Revenue Growth: Revenue and annual recurring revenue are rising year over year, with continued increases through 2024 and into the first nine months of 2025 per the S-1. Deferred revenue also increased over the latest period, pointing to momentum in contracted business.

Investor Backing & Capital Strength: A $150M growth round in mid-2025 and a filed S‑1 for an NYSE listing indicate sustained access to capital and capital-markets readiness. Headcount scale and participation from established investors further underline financing support for expansion.

Customer Loyalty & Retention: Core and Large customer counts expanded across 2023–2025 with net dollar retention above 100% and higher for large accounts. Enterprise traction is reflected in rising numbers of large customers and continued spend expansion within accounts.

Diversified Revenue Streams: Non‑COVID portfolio momentum across oncology, vaccines, and cardiovascular is contributing, with Eliquis, Prevnar, Vyndaqel, and Seagen‑derived assets cited as growth drivers. This breadth helps offset the normalization of COVID products.

Cost & Operational Efficiency: Adjusted diluted EPS rose in 2025 versus 2024, attributed to cost realignment and mix. Ongoing cost‑saving and manufacturing optimization programs are intended to support margins through mid‑decade.

Future-Ready Strategy: Management highlights oncology and next‑generation assets, with Seagen’s ADC platform and pending data/approvals expected to support medium‑term growth. Pipeline catalysts into 2026 position the company for potential re‑acceleration if execution lands as planned.

Strong Revenue Growth: Feedback suggests annualized revenue surpassed $200M, later crossing $300M, with growth reported at a rapid pace over the past two years. These run‑rate milestones indicate strong top‑line momentum.

Profitability: Feedback suggests the company reached EBITDA break‑even at the end of 2024. This milestone supports improved operating discipline alongside growth.

Investor Backing & Capital Strength: Feedback suggests a $200M Series E in early 2025 nearly doubled valuation to $2.7B and brought in new prominent growth investors. This capital base signals confidence in continued scaling and provides resources for expansion.

Strong Hiring & Retention: Public profiles indicate a team size around 13 with multiple open roles across engineering and operations. This post‑accelerator hiring cadence suggests active headcount expansion.

Strategic Partnerships: Company materials cite a multimillion‑dollar contract with a leading foundation lab described as that lab’s largest to date. This signals deepening commercial ties with top‑tier AI labs.

Investor Backing & Capital Strength: The startup is backed by Y Combinator (Summer 2025) with an accelerator/pre‑seed investment around $500K noted by public databases. This provides institutional support and early capital to scale operations.

Market Expansion: Public signals indicate hubs in Chicago and Medellín and a 2022 acquisition that established a LATAM development hub, suggesting scaled delivery capacity. Feedback suggests active hiring across the U.S. and LATAM supports this broader footprint.

Strategic Partnerships: The company is presented as an Optimizely (Episerver) solution partner with certifications and specializations, alongside listings on partner pages like Umbraco. These partnership standings typically align with steady deal flow and team capacity.

Innovation-Driven Growth: Adage highlights AI-enabled solutions and productized offerings such as ACE Commerce and SmartSeat, with recent AI orchestration content and product updates. The addition of a VP, Innovation & Technology role points to investment in modern capabilities and leadership to drive growth.